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Abstract
Purpose of Review The purpose of this review is to discuss the risk of bacterial cross-infection for bronchiectasis patients in the
outpatient setting. Cross-infection has primarily been a matter of concern in cystic fibrosis (CF). There is considerable evidence
of transmission of pathogens between CF patients, and this has led to guideline recommendations advocating strict segregation
policies. Guidelines in bronchiectasis do not specifically address the issue of cross-infection. If cross-infection is prevalent, it may
have significant implications for patients and the practical running of specialist care.
Recent Findings Multiple UK-based studies have now published evidence of cross-infection with Pseudomonas aeruginosa
within cohorts of bronchiectasis patients; however, the risk does not appear to be high. There is also evidence suggesting cross-
infection from CF patients to bronchiectasis patients.
Summary The current evidence for cross-infection in bronchiectasis is limited, but suggests a small risk with Pseudomonas
aeruginosa. Longitudinal studies looking at Pseudomonas aeruginosa and other pathogens are now required.
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Introduction
The clinical entity of non-cystic fibrosis bronchiectasis, here-
after referred to as simply bronchiectasis, has been recognised
since at least the nineteenth century when it was described by
Rene Laënnec [1]. Today, a diagnosis of bronchiectasis re-
quires abnormally dilated bronchi on radiological examina-
tion, a clinical presentation of a cough with sputum production
and recurrent respiratory infections and the exclusion of cystic
fibrosis (CF). Bronchiectasis had previously been seen as an
orphan disease of decreasing relevance [2]; however, this is no
longer the case [3, 4, 5•]. The establishment of registries, such
as EMBARC in Europe and the Bronchiectasis and NTM
Research Registry in North America, have highlighted the
renewed interest in this condition. While global estimates of
prevalence are highly variable, it is also likely that current
figures underestimate the true disease burden. Despite height-
ened awareness, a diagnosis can be significantly delayed or
wrongly labelled as purely chronic obstructive pulmonary dis-
ease [6–8].
The principles of managing bronchiectasis continue to be
based around the vicious cycle hypothesis set out by Peter
Cole (see Fig. 1) [9–11]. A key part of this management strat-
egy is dealing with the bacteria colonising these patients.
Certain pathogens are consistently found in microbiological
studies of bronchiectasis and include Pseudomonas
aeruginosa, Haemophilus influenzae, Staphylococcus aureus,
Streptococcus pneumoniae and Moraxella catarrhalis
[12–15]. A further growing concern involves the non-
tuberculous mycobacteria (NTM). Colonisation with patho-
gens is associated with disease severity, with P. aeruginosa
being particularly implicated [12, 16]. Thus, it would seem
logical that avoidance of colonisation by these pathogens
would be advantageous. After a number of studies have sug-
gested cross-infection of pathogens between patients in cystic
fibrosis cohorts, more recent work has started to explore this
issue in bronchiectasis. In this review article, we consider the
risk of patients with bronchiectasis acquiring these pathogens
in the outpatient setting from other patients.
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Cross-Infection in Cystic Fibrosis—a Reason
for Concern in Bronchiectasis
The suspicion of cross-infection in bronchiectasis is unsurpris-
ing given the evidence from the CF community concerning
patient-to-patient transmission of the Burkholderia cepacia
complex and P. aeruginosa. Evidence that cross-infection
was occurring became apparent from studies involving pa-
tients: in frequent close contact [17, 18]; in social proximity
within holiday camps [17, 19–23]; and within clinical envi-
ronments [24–28]. Infamous strains associated with increased
morbidity and mortality were described, such as the ET12
strain ofBurkholderia cenocepacia and the Liverpool epidem-
ic strain of P. aeruginosa [29–31]. Cross-infection was not a
universal finding in epidemiological studies, yet the practice
of CF holiday camps was ceased and rigorous infection con-
trol policies were introduced into clinical settings [32, 33].
Current examples include the cohorting of clinics by
colonising pathogen, preventing direct contact between pa-
tients and rotating staff rather than patients through consulta-
tion rooms. The demonstrated benefits of these policies have
included delayed chronic infection, stopping the spread of a
common strain, and reduced prevalence of a transmissible
strain [34–37].
A new major concern of cross-infection in the CF commu-
nity has subsequently arisen. Whole genome sequencing of
Mycobacterium abscessus isolates has suggested possible
cross-infection [38, 39]. This is particularly concerning as
the transmissibility of this pathogen would have emerged in
the CF community despite segregation and other infection
control policies.
“Proving” Cross-Infection
While the research in the CF community has claimed cross-
infection, it is exceedingly difficult to prove. In reality, what is
assessed is the likelihood of cross-infection, as opposed to the
acquisition of pathogens from the environment. A variety of
factors need to be considered for a reliable risk assessment.
An essential starting point for considering cross-infection is
examining the evidence of shared strains between patients.
However, the identification of a shared strain can be technique
dependent [40]. From the early cross-infection studies in the
CF community, through to current whole genome sequencing-
based work, a wide range of techniques have been used with
varying degrees of capability and robustness. These methods
can be broadly split into the molecular fingerprinting tech-
niques generally seen in older studies and sequencing-based
techniques that are more common in modern studies.
Molecular fingerprinting techniques, such as pulsed-field
gel electrophoresis (PFGE) and random amplified polymor-
phic DNA (RAPD), often involve the amplification of DNA
by polymerase chain reaction (PCR) and the subsequent sep-
aration of products on a gel. This allows visual examination,
either by eye or computer, to identify sufficiently similar pat-
terns as the same strain. However, these techniques are sus-
ceptible to interpretive bias and poor inter-laboratory
reproducibility.
Sequencing techniques are increasingly common and in-
clude whole genome sequencing, but also the simpler multi-
locus sequence typing (MLST), a technique which sequences
only a few housekeeping genes, with the outputs entered into a
global database. This is a highly reproducible scheme with
straightforward naming and subsequent identification of
shared strains. This scheme also allows easy strain identifica-
tion from whole genome sequencing data as these housekeep-
er genes will already have been sequenced. However, MLST
is clearly not as detailed as whole genome sequencing as far
less genetic material is analysed.
The mere identification of a shared strain by a robust tech-
nique is insufficient to prove cross-infection. It is clear from
epidemiological studies that some strains of bacteria are com-
mon in patients and the general environment, such as the P.
aeruginosa strain known as Clone C [41, 42]. Consequently,
when two patients share a previously described transmissible
Fig. 1 The vicious cycle
hypothesis based on Peter Cole’s
original description
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strain not found in the environment, it is more likely that
cross-infection has occurred rather than environmental acqui-
sition, as opposed to patients sharing a strain like Clone C
which is known to be common in the environment.
Therefore, knowledge of both the shared strain and its envi-
ronmental prevalence is important.
Further evidence that increases the likelihood of cross-
infection is a plausible acquisition route. In general, it is felt
that human-to-human transfer of respiratory pathogens takes
place by direct and indirect contact transmission, droplet
transmission and airborne transmission [32, 43]. Droplet
transmission generally refers to particles greater than 5 μm
in diameter which do not remain airborne, as opposed to air-
borne droplet nuclei, which are smaller than 5 μm and can be
inhaled [44]. Cross-infection with droplet nuclei is of particu-
lar concern. Knibbs et al. demonstrated that cough aerosols
containing viable P. aeruginosa could travel at least 4 m and
be detected in air after 45 min [43]. This time period was
consistent with a previous aerobiological model of viable P.
aeruginosa [45]. An older study found evidence of a trans-
missible strain via air sampling 1–3 h after patients left their
ward room. The same strain of P. aeruginosa was also found
when sampling ward corridors, spirometry tubing and chairs
after use by patients known to be colonised with it [46]. It is
possible that survival in aerosols may be enhanced in strains
expressing a mucoid phenotype—a common finding in chron-
ic CF strains [45].
Reviewing CF studies, it appeared that by solely
implementing measures against contact and droplet transmis-
sion, halting the spread of transmissible strains was still not
achieved without strict segregation [47, 48]. This adds weight
to concerns of airborne transmission via droplet nuclei being a
major factor in cross-infection. Consequently, it is conceivable
that patients may never physically meet yet may cross-infect.
While epidemiological studies cannot identify every occasion
where patients have shared an environment, it may be possible
to identify some temporal relationship. For example, in previ-
ous CF studies, cross-infection may have occurred during hol-
iday camp attendance, while in recent bronchiectasis studies,
this could have been during attendance at an outpatient clinic
or a pulmonary rehabilitation course.
Finally, understanding the behaviour and potential muta-
tion rates of the bacteria contributes to the assessment of trans-
mission risk. This understanding is potentially critical when
using whole genome sequencing data. An issue with whole
genome sequencing in cross-infection studies is determining
when genetic difference between samples is significant. This
is particularly important when assessing whether cross-
infection has occurred in respiratory cohorts under long-term
follow-up. The longer that patients have been colonised with a
particular pathogen, the greater the plausible genetic diver-
gence in potential cross-infection cases. Significant diver-
gence within an individual patient’s lung is also possible
[49••], and when transmitted to the lungs of another patient,
these pathogens may show even further genetic divergence
when subjected to different pressures. Examples of pressures
include the use of a long-term inhaled antibiotic or the pres-
ence of hypermutator genes. Previous work has illustrated that
hypermutators are not uncommon in diseased lungs [50].
Consequently, an understanding of standard mutation rates,
the awareness of and testing for hypermutators and an approx-
imation of how long the patient may have had the strain may
all influence the likelihood of cross-infection.
It is clear that we need to think in terms of risk and likeli-
hood when considering cross-infection in respiratory cohorts
with chronic colonisation. There are many facets to these con-
siderations and with our current knowledge and technologies,
these assessments have changed from those of the early CF
studies.
Cross-Infection in Bronchiectasis
As previously mentioned, whilst the investigation of cross-
infection is a long-running narrative in CF, it is only starting
to be addressed in bronchiectasis. After considering cross-
infection in CF, the same issues in bronchiectasis cohorts are
clearly plausible.Without guidelines advising segregation, pa-
tients will either come into direct contact, or at least share
facilities within a short time period. In the outpatient setting,
this could include shared waiting areas; the use of rooms for
lung function testing and consultations with healthcare profes-
sionals; and patients passing through a hospital pharmacy or
café. A higher risk environment may be pulmonary rehabili-
tation courses, where patients may spend many hours together
whilst performing exercise. As specialist outpatient atten-
dance and pulmonary rehabilitation is key to good disease
management [51, 52], it is important to have an appreciation
of the risk of cross-infection. In the last 5 years, there have
been three particularly relevant pieces of research which begin
to quantify that risk, though all three solely address P.
aeruginosa (see Table 1) [49••, 53••, 54••].
The first of these, published by De Soyza et al., was an
epidemiological review of P. aeruginosa in an outpatient set-
ting in the North-East of England [53••]. Of the 40 patients
studied, 36 were seen within a specialist bronchiectasis outpa-
tient service. The authors reported that cross-infection almost
certainly occurred between two patients. This study was piv-
otal as it was the first to report evidence that cross-infection in
the outpatient setting may be occurring between bronchiecta-
sis patients. Crucially, if it had occurred, it did not appear to be
a common event. Two separate genotyping techniques were
used for robustness on all samples, with additional analysis
with a further technique (PFGE) in the case of possible cross-
infection. It is worth pointing out that the bronchiectasis ser-
vice was run on a different site to the local CF services, and as
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the authors comment, this may have influenced the findings.
In other settings, CF and bronchiectasis patients may use the
same clinic rooms and see the same healthcare providers. Also
of note in this study, there is no reporting of multiple isolates
being assessed from each sputum sample. It is clearly not
feasible to assess all the colonies seen on a bacterial culture
plate; however, this may result in an underestimation of the
presence of shared strains.
A contrasting study was published by Hilliam et al. in
which whole genome sequencing data was presented from
91 patients attending 16 different bronchiectasis centres
[49••]. This provided a useful overview of the strains of P.
aeruginosa common in the UK and highlighted that ubiqui-
tous environmental strains were found in patients, suggesting
common environmental acquisition. This multi-centre study
was less able to comment on local cross-infection; however,
there were cases of closely related bacterial isolates from dif-
ferent patients within the same centre. It is of some re-
assurance that there was no suggestion of a widespread, na-
tionally transmissible strain, though the lack of genetic diver-
sity between some isolates highlights the possibility that
cross-infection could be occurring. The study also demonstrat-
ed that patients can be infected with multiple bacterial line-
ages. This re-enforces how analysing single isolates from cul-
ture samples may risk missing additional strains.
The final study of note examined a single-centre cohort of
46 bronchiectasis patients in the South-West of England
[54••]. The study included three genotyping techniques
(RAPD, MLST and whole genome sequencing) assessing 10
isolates per sample, and investigated historical microbiologi-
cal data and hospital attendance. Attempts were made to fur-
ther interpret genetic differences in shared strains via an in
silico prediction of hypermutator status and by incorporating
publicly available genomes of the shared strains into the anal-
ysis. Multiple shared strains were found and the majority were
felt to be due to environmental acquisition. However, one
shared strain was identified (ST564), which has rarely been
described in the environment, and was highly genetically sim-
ilar between three patients. An episode when two of the three
patients shared facilities could be identified, and it was felt that
cross-infection was highly likely. It should be noted that when
considering previous microbiological data, this event may
have been a case of super-infection. To highlight the influence
of higher resolution genotyping in risk assessment, it is worth
noting this cohort had previously been presented in abstract
form after RAPD and MLST had been performed [55], and
the perceived likelihood of cross-infection having occurred
increased after the addition of whole genome sequencing anal-
ysis. This study also assessed the local CF population as well
as non-respiratory isolates and ST564 was not found else-
where. There was also no evidence of cross-infection between
the bronchiectasis and CF cohorts.
This publication, as well as the other two main studies,
lacks longitudinal data which would help give more context
to the importance of this potentially transmissible strain. The
studies also lack epidemiological data for pathogens in the
outpatient environment, such as from the water supplies.
Consequently, we do not have evidence, either for or against,
of acquisition from the outpatient facilities.
The authors of the final study suggest that a change in
segregation policy is not recommended. This is following
consideration of both the likely rare occurrence of cross-infec-
tion, and the potential disadvantages of this strict approach.
However, it may be the case that the risk is greater in situations
where bronchiectasis patients share facilities with CF patients.
A case report describes highly likely transmission of P.
aeruginosa to a bronchiectasis patient who had shared accom-
modation and physiotherapy with CF patients [56], and anoth-
er series suggests that patients with bronchiectasis had been
potentially infected with transmissible strains of P. aeruginosa
from CF patients during inpatient admissions [57•]. Despite
the absence of reported transmission of other bacteria between
CF and NCFB patients (notably, NTM, S. aureus or H.
influenzae), it would seem sensible that bronchiectasis
Table 1 Summary of studies suggesting evidence of cross-infection with P. aeruginosa in bronchiectasis
Authors Sample
sizes
Outpatient setting Genotyping techniques Likelihood of cross-infection
De Soyza A et al.
Eur Respir J. 2014
[53••]
40 patients
56 isolates
Single-centre
CF managed on different
site
- ArrayTube genotyping
- Variable number tandem repeat
(VNTR) analysis
- Pulsed-field gel electrophoresis
“Only one probable case of
cross-infection”
Hilliam Y et al.
Eur Respir J. 2017
[49••]
91 patients
189 isolates
Multi-centre
(16 “non-CF
bronchiectasis” centres)
- Whole genome sequencing Closely related isolates found between
patients “implying the possible
occurrence of cross-infection”
Mitchelmore PJ et al.
Thorax. 2017 [54••]
46 patients
459 isolates
Single-centre
CF managed on same site
- Random amplification of
polymorphic
DNA
- Multi-locus sequence typing
- Whole genome sequencing
A shared strain identified between three
patients had little genetic difference.
Believed to be “indicative of
cross-infection”
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patients who are managed within a CF service should be sub-
ject to the same infection control measures in order to reduce
the risk of transmission. This is consistent with a recent work-
ing group consensus statement involving prominent European
networks and a patient group [58••].
Future Research Needs
The possibility of cross-infection between bronchiectasis pa-
tients in the outpatient setting is clearly plausible and is a
research concern for the bronchiectasis community [59]. At
present, there is insufficient evidence of a significant risk to
patients, which may be due to the limited quantity of relevant
work. Currently, only cross-infection with P. aeruginosa has
been investigated but this has been in small numbers and
compounded by a lack of longitudinal data. The rates of P.
aeruginosa colonisation are lower in bronchiectasis patients
than in CF [53••], and hospital attendances are typically
shorter. Therefore, if there was a transmissible strain within
a cohort, it would likely take longer to reveal itself, and follow
up data would require an adequate interval. Longitudinal stud-
ies would also help to clarify whether or not putative trans-
missible strains persist. Taking things forward, large longitu-
dinal studies with high-resolution genotyping and detailed ep-
idemiological data collection are required for P. aeruginosa,
as well as other significant pathogens. In light of the increas-
ing incidence and prevalence of non-tuberculous mycobacte-
rial-pulmonary disease and concerns in the CF community of
NTM cross-infection [38, 39, 60], in certain circumstances,
these studies should include M. abscessus.
If future work reveals evidence of transmissible pathogens,
further research should look into strain pathogenicity, examine
infection control policies such as segregation or face-mask
wearing and ultimately investigate the clinical impact of in-
fection control policies.
Although performing these studies is clearly important,
gaining a better understanding of molecular techniques and
data interpretation is also essential. This may focus around
whole genome sequencing and the interpretation of genetic
difference between samples. We are not yet able to clearly
define the significance of genetic difference; therefore, an un-
derstanding of divergence is crucial.
Conclusion
At present, the evidence for the risk of cross-infection in the
outpatient setting is very limited. There is evidence of likely
cross-infection with P. aeruginosa, although these episodes
seem to be rare. With potentially growing cohorts, and the
promotion of bronchiectasis-specific clinics and pulmonary
rehabilitation programmes, further high-quality research is
required to investigate cross-infection risk by P. aeruginosa
and other pathogens. With our current knowledge base, adher-
ence to sensible basic infection control measures should be
standard practice, without the imposition of stricter segrega-
tion policies [58••].
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